Zytiga is a potent CYP17 inhibitor that works by preventing the biosynthesis of all androgens in the body. Resistance to Zytiga is a serious problem in urology leaving few alternative options post Zytiga. Resistance to Zytiga is believed to be mediated by the PI3K and Akt signalling pathway and 2 drugs (GDC0980 and GDC0068 respectively) that are inhibitors of these 2 molecular targets are under clinical investigation in combination with Zytiga.
Salvestrol Q40 has been shown to be a potent inhibitor of the PI3K/Akt signalling pathway, and itself has powerful anticancer effects mediated by the enzyme CYP1B1. Salvestrol Platinum contains a very high concentration of salvestrol Q40 and this supplement would potentiate the activity of Zytiga in metastatic tumour regression activity as well as providing prevention against PI3K/Akt mediated Zytiga resistance. One capsule daily of Salvestrol Platinum is sufficient for prevention of Zytiga resistance but higher doses up to 6 capsules daily can be used for maximum combined therapeutic effect.
No comments:
Post a Comment